Read More Pharma Industry News FDA extends review period for Humacyte’s vascular trauma treatment ATEV The U.S. Food and Drug Administration’s review of Humacyte, Inc.’s innovative vascular trauma treatment, known as the acellular… byPallavi MadhirajuAugust 10, 2024